Talphera (TLPH) Change in Accured Expenses (2010 - 2026)
Talphera (TLPH) posted Change in Accured Expenses of $787000.0 for Q2 2026, up 412.3% on a QoQ basis from -$252000.0 in Q1 2026, and up 500.76% year-over-year from $131000.0 in Q2 2025.
Powered by 
Analysis
Talphera (TLPH) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Talphera has reported Change in Accured Expenses for 17 years, with the latest figure at $787000.0 in Q2 2026.
- On a quarterly basis, Change in Accured Expenses rose 500.76% year-over-year to $787000.0 in Q2 2026; TTM through Jun 2026 was $2.0 million, a 393.89% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 205.11% from the prior year.
- Change in Accured Expenses was $787000.0 for Q2 2026 at Talphera, up from -$252000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $891000.0 in Q3 2025, with the low at -$1.5 million in Q1 2022.
- Average Change in Accured Expenses over 5 years is -$119388.9, with a median of -$128500.0 recorded in 2022.
- The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses plunged 538.57% in 2023, then jumped 991.0% in 2025.
- Over 5 years, Change in Accured Expenses stood at -$157000.0 in 2022, then surged by 500.64% to $629000.0 in 2023, then sank by 161.84% to -$389000.0 in 2024, then jumped by 240.36% to $546000.0 in 2025, then surged by 44.14% to $787000.0 in 2026.
- The last three Change in Accured Expenses figures came in at $787000.0 (Q2 2026), -$252000.0 (Q1 2026), and $546000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -13.91 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 787,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 787,000.00 |
| Mar 31, 2026 | -252,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Sep 30, 2025 | 891,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | -313,000.00 |
| Dec 31, 2024 | -389,000.00 |
| Sep 30, 2024 | -100,000.00 |
| Jun 30, 2024 | 401,000.00 |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | 629,000.00 |
| Sep 30, 2023 | -354,000.00 |
| Jun 30, 2023 | -447,000.00 |
| Mar 31, 2023 | -960,000.00 |
| Dec 31, 2022 | -157,000.00 |
| Sep 30, 2022 | 126,000.00 |
| Jun 30, 2022 | -70,000.00 |
| Mar 31, 2022 | -1.51 Mn |
| Dec 31, 2021 | -311,000.00 |
| Sep 30, 2021 | 1.35 Mn |